LIVZON PHARMA - Livzon Pharmaceutical Group Co., Ltd.'s progress announcement on the "Double Improvement of Quality and Return" action plan
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to set forth the "Livzon Pharmaceutical Group Co., Ltd." published on the website of the Shenzhen Stock Exchange
Co., Ltd.’s Progress Announcement on the Action Plan to Improve Quality and Return” is for reference only.
By order of the board of directors
Livzon Pharmaceutical Group Co., Ltd.
LivzonPharmaceuticalGroupInc.*
company secretary
Liu Ning
China, Zhuhai
August 21, 2026
As of the date of this announcement, the Company’s executive directors are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman); the Company’s non-executive directors are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Company’s employee directors are Ms. Ran Yongmei; and the Company’s independent non-executive directors are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.
*Identification only
Securities code: 000513, 01513 Securities abbreviation: Livzon Group, Livzon Pharmaceutical Announcement Number: 2026-54
Livzon Pharmaceutical Group Co., Ltd.
Announcement on the progress of the "Double Improvement of Quality and Return" action plan
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete and contains no false records, misleading statements or major omissions.
In order to conscientiously implement the guiding ideology of "activating the capital market and boosting investor confidence" proposed by the Political Bureau of the Central Committee and "vigorously improve the quality and investment value of listed companies and take more effective measures to stabilize the market and stabilize confidence" proposed by the Political Bureau of the Central Committee, safeguard the interests of all shareholders of Livzon Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), and further enhance the company's quality and investment value, the company has formulated an action plan of "double improvement of quality and return". The implementation of the company's "double improvement of quality and return" action plan is as follows:
- Focus on the main business and lead the pace of high-quality development through innovation
The company has always adhered to the mission of "putting patients' life quality first" and the vision of "being a leader in the pharmaceutical industry", focusing on the field of life and health, continuing to be oriented by patients' clinical needs, improving research and development efficiency through AI, and further strengthening its leading advantages in innovative drugs and high-barrier complex preparation platforms. At the same time, we will increase management innovation, comprehensively improve the company's sustainable development capabilities, actively respond to changes in industry policies, and promote the company's high-quality development. 2. Investor-oriented, actively pay dividends, buy back large sums, and share development results
Based on the company's operating performance and overall financial situation in 2025, the board of directors passed the 2025 profit distribution plan as follows: based on the total share capital on the equity registration date determined by the implementation of the 2025 profit distribution plan (excluding the number of shares that have been repurchased but not canceled by the company), a cash dividend of RMB 14.30 (including tax) will be distributed to all shareholders of the company for every 10 shares. No bonus shares will be issued this time, and no capital reserve will be converted into share capital.
In order to enhance the long-term investment value of the company's stocks, safeguard the interests of investors, and enhance investor confidence, based on the high recognition of the company's value and confidence in future development, the company's shareholders will resolve to implement the repurchase of A shares and H shares in 2024, and will continue to implement it in 2025. The purpose of the repurchase is to cancel registered capital. In 2025, the company used a total of RMB 572.7232 million (excluding transaction costs) to repurchase 15.4695 million A shares; a total of HKD 7.3728 million (excluding transaction costs) was used to repurchase 271,600 H shares. All repurchased shares have been cancelled.
- Carry out multi-dimensional investor relations activities and continue to improve the quality of information disclosure
Since its listing, the company has always attached great importance to the quality of domestic and foreign investor relations and is committed to institutionalizing and normalizing investor relations work. The company has revised the company's "Information Disclosure Management Measures", "Investor Relations Management System" and other systems in accordance with relevant regulations such as the Securities Law of the People's Republic of China, the Company Law of the People's Republic of China, the Information Disclosure Management Measures for Listed Companies, the Stock Listing Rules of the Shenzhen Stock Exchange. The company has established diversified communication channels through performance promotion meetings, reverse roadshows for institutional investors, brokerage strategy meetings, and interactive platforms. As a representative of Shenzhen listed companies, the company participated in the "In-depth R&D and Improvement·Accumulating New Momentum for Pharmaceutical Growth" 2025 organized by the Shenzhen Stock Exchange. The annual collective performance briefing also actively uses visual communication forms such as videos and quick pictures to vividly display the company's achievements in production and operation, R&D innovation, ESG and other aspects. Through disclosure forms that are easier for investors to interpret and information platforms with higher frequency of contact, publicity and interpretation are streamlined and efficient, and the readability and accessibility of the company's announcements are enhanced. The company has received the highest information disclosure rating (Grade A) from the Shenzhen Stock Exchange for six consecutive years.
In addition, during the reporting period, the company adhered to the orientation of investor demand, continued to deepen the application of investment data management middle platform and AI tools, strengthened the collection and analysis of investors' focus and market feedback, carried out hierarchical and classified communication around key issues such as operating performance, R&D innovation, international layout and shareholder returns, actively responded to investor concerns, and promptly fed back investor opinions and suggestions to the management. The company will continue to improve the investor communication mechanism, smooth communication channels for domestic and foreign investors, enhance investors' understanding and recognition of the company's development strategy and long-term investment value, and continuously improve the accuracy, timeliness and effectiveness of investor relations management. 4. Continue to improve corporate governance and promote long-term sustainable development
As an A+H-share listed company, the company actively implements the ESG development concept on the basis of summarizing past governance practical experience, starting from the system and organizational structure, and using practical actions to further improve the level of corporate governance.
Since 2016, the company has achieved the preparation and disclosure of high-quality ESG reports for 10 consecutive years. With the in-depth implementation of ESG strategies, the company continues to create a solid core for growth and continuously builds new driving forces for sustainable development. The company further deepens environmental management and climate action: it continues to promote carbon inventory work, and on the basis of completing scope 1 and 2 verifications, it carries out scope 3 carbon emission accounting covering the entire value chain for the second consecutive year to fully understand the carbon emissions footprint; at the same time, it reviews the completion of established environmental goals, updates assessment indicators based on industry trends and business development, and scientifically sets a new round of environmental management and carbon emission reduction targets for 2026-2030, laying an implementation path for medium- and long-term sustainable development.
From 2025 to the first half of 2026, the company's ESG results have been highly recognized by authoritative institutions at home and abroad: it has been selected into S&P Global's "Sustainable Development Yearbook" for three consecutive years, and ranked among the "Best 5% of Chinese Enterprises in S&P CSA Ratings"; it has been rated by Wind ESGAA for consecutive years, won the Wind "Top 100 ESG Best Practices of Chinese Listed Companies in 2025", and was selected into the "Best Practice Cases of Sustainable Development of Chinese Listed Companies" and "English Case Collection of ESG Practices of Shenzhen Listed Companies". In addition, the company has an ESG rating of A from the London Stock Exchange and was selected into the Hang Seng A-share Sustainability Corporate Benchmark Index. At the same time, it was selected into the Hong Kong Stock Exchange Technology 100 Index for its comprehensive capabilities in technology-driven and sustainable development, which fully demonstrates the company's comprehensive strength and continuous progress in environmental, social and governance aspects.
Announcement is hereby made.
Board of Directors of Livzon Pharmaceutical Group Co., Ltd.
August 22, 2026